Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

BCLI
BRAINSTORM CELL THERAPUTC
stock OTC

EOD
Aug 6, 2025
0.6100USD+5.191%(+0.0301)62,152
Pre-market
0.00USD-100.000%(-0.58)0
After-hours
0.00USD0.000%(0.00)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 27, 2022
07:01AM EST  BrainStorm Cell Therapeutics to Present at the 12th Annual California ALS   PR Newswire
Jan 4, 2022
07:01AM EST  BrainStorm Cell Therapeutics to Present at Biotech Showcase(tm) 2022   PR Newswire
Dec 27, 2021
07:15AM EST  BrainStorm Cell Therapeutics Inc. (BCLI) said the FDA recommended that the company submit an EAP protocol amendment to provide additional dosing of NurOwn for participants who completed the Expanded Access Protocol. Under the amended EAP protocol, eligible participants will receive up to 3 additional doses.   RTTNews
07:02AM EST  BrainStorm Cell Therapeutics : FDA Authorizes Further NurOwn Dosing Under Expanded Access Program   RTTNews
07:02AM EST  BrainStorm Cell Therapeutics Announces FDA Authorizes Further NurOwn Dosing Under Expanded Access Program   Benzinga
07:01AM EST  FDA Authorizes Further NurOwn(r) Dosing Under Expanded Access Program   PR Newswire
Dec 13, 2021
07:01AM EST  BrainStorm Cell Therapeutics Announces peer reviewed publication of NurOwn's(r)   PR Newswire
Dec 7, 2021
07:09AM EST  BrainStorm Cell Therapeutics And Catalent Announce Completion Of Technology Transfer For NurOwn Manufacturing   Benzinga
07:01AM EST  BrainStorm Cell Therapeutics and Catalent Announce Completion of Technology   PR Newswire
Dec 2, 2021
07:01AM EST  BrainStorm Cell Therapeutics to Present New Biomarker Data on NurOwn(r) at the   PR Newswire
Nov 30, 2021
04:02PM EST  BrainStorm Cell ALS Candidate Shows Benefit In Patients With Less Severe Disease   Benzinga
Nov 29, 2021
08:10AM EST  BrainStorm: Analyses Show Effect Of NurOwn On ALS Disease   RTTNews
07:38AM EST  BrainStorm Cell Announces Presentation Of New Analyses From Phase 3 Trial Of NurOwn In ALS   RTTNews
07:32AM EST  BrainStorm Cell Therapeutics Announces The Presentation Of New Analyses From The Phase 3 Trial Of NurOwn In ALS At The 4th Annual ALS ONE Research Symposium   Benzinga
07:31AM EST  the Phase 3 Trial of NurOwn(r) in ALS at the 4th Annual ALS ONE Research Symposium   PR Newswire
Nov 22, 2021
05:31AM EST  BCLI: Biomarkers Predict Response in ALS Phase 3   Benzinga
Nov 15, 2021
11:07AM EST  Earnings Scheduled For November 15, 2021   Benzinga
10:52AM EST  Brainstorm Cell Q3 EPS $(0.15) Beats $(0.20) Estimate   Benzinga
07:13AM EST  BrainStorm Cell Therapeutics Q3 Net Loss $5.3 Mln Vs. Net Loss $4.5 Mln Last Year   RTTNews
07:01AM EST  BrainStorm Cell Therapeutics Announces Third Quarter 2021 Financial Results and   PR Newswire
Nov 8, 2021
07:01AM EST  BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical   PR Newswire
Oct 28, 2021
06:01AM EDT  Brainstorm Cell Therapeutics Announces Appointment of Menghis Bairu, MD, to   PR Newswire
Oct 25, 2021
07:01AM EDT  BrainStorm to Announce Third Quarter Financial Results and Provide a Corporate   PR Newswire
Oct 18, 2021
07:38AM EDT  BrainStorm Announces Scientific Presentation Of NurOwn Exosome Preclinical ARDS Data At NYSCF 2021 VIRTUAL Meeting   Benzinga
07:32AM EDT  BrainStorm Announces Scientific Presentation Of NurOwn Exosome Preclinical ARDS Data   RTTNews
07:31AM EDT  BrainStorm Announces Scientific Presentation of NurOwn(r) Exosome Preclinical   PR Newswire
Oct 14, 2021
07:09AM EDT  BrainStorm : Phase 2 Clinical Trial Data Of NurOwn In Progressive MS Will Be Presented   RTTNews
07:07AM EDT  BrainStorm Cell Therapeutics Announces Phase 2 Clinical Trial Data Of NurOwn In Progressive MS Will Be Presented At The 37Th Congress Of The European Committee For Treatment And Research In Multiple Sclerosis   Benzinga
07:02AM EDT  the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)   PR Newswire
Oct 6, 2021
05:01PM EDT  BrainStorm to Present ALS Phase 3 Biomarker Analyses at Annual NEALS Meeting   PR Newswire
05:01PM EDT  BrainStorm to Present ALS Phase 3 Biomarker Analyses at Annual NEALS Meeting October 6th, 2021   Benzinga
Oct 4, 2021
06:01AM EDT  BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa   PR Newswire
Oct 1, 2021
07:32AM EDT  BrainStorm To Present Phase 2 Progressive MS Study Results In Oral Presentation At 37th Congress Of ECTRIMS   RTTNews
07:31AM EDT  BrainStorm To Present Phase 2 Progressive MS Study Results In Oral Presentation At 37th Congress Of ECTRIMS Oct. 14   Benzinga
07:29AM EDT  BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation   PR Newswire
06:06AM EDT  BrainStorm Cell Therapeutics To Present Phase 2 Data Results At Congress of the European Committee for Treatment and Research in Multiple Sclerosis Oct. 14 At 10:45 a.m. EDT   Benzinga
Sep 25, 2021
11:21AM EDT  TENX: Second Quarter Results   Benzinga
Aug 9, 2021
04:59PM EDT  BrainStorm Cell Therapeutics S-3 Shows Registration For $200M Mixed Securities Shelf Offering   Benzinga
Aug 6, 2021
12:12PM EDT  BCLI: Weighing Options for How Best to Advance NurOwn   Benzinga
Aug 5, 2021
07:08AM EDT  Brainstorm Cell Q2 EPS $(0.17) Beats $(0.20) Estimate   Benzinga
07:01AM EDT  BrainStorm Announces Second Quarter 2021 Financial Results and Provides a   PR Newswire
04:08AM EDT  Earnings Scheduled For August 5, 2021   Benzinga
Jul 27, 2021
06:01AM EDT  BrainStorm Increases Commercial Manufacturing Capacity; Granted GMP   PR Newswire
Jul 26, 2021
06:01AM EDT  BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate   PR Newswire
Jun 15, 2021
09:23AM EDT  Brainstorm Cell Therapeutics Announces Grant Of Multiple Patents For NurOwn   Benzinga
09:22AM EDT  Brainstorm Announces Expansion of NurOwn(r) IP Portfolio with Grant and   PR Newswire
May 25, 2021
04:22PM EDT  BrainStorm Announces Scientific Presentation of NurOwn(r) Exosome Preclinical   PR Newswire
04:22PM EDT  BrainStorm Cell Therapeutics Highlights Presentation Of Poster 'Molecular Mechanisms Underlying MSC-NTF (NurOwn) Exosome Benefits in a Mouse LPS-induced ARDS Model' At Upcoming Meeting On May 25 At 8 p.m. EDT   Benzinga
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 6, 2021
10:06AM EDT  Brainstorm Cell Therapeutics US Patent & Trademark Office Abstract For Co.'s 'METHODS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS'   Benzinga
Apr 28, 2021
02:21PM EDT  BCLI: Continuing to Receive Feedback on Next Steps for   Benzinga
Apr 26, 2021
01:29PM EDT  Brainstorm Cell Therapeutics shares were trading lower after the company reported Q1 earnings results.   Benzinga
07:20AM EDT  BrainStorm Q1 Loss Per Share $0.19 Vs $0.32 Last Year   RTTNews
07:06AM EDT  Brainstorm Cell Q1 EPS $(0.19) Beats $(0.26) Estimate   Benzinga
07:01AM EDT  BrainStorm Announces First Quarter 2021 Financial Results and Provides a   PR Newswire
04:24AM EDT  Earnings Scheduled For April 26, 2021   Benzinga
Apr 24, 2021
09:24AM EDT  The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx   Benzinga
Apr 21, 2021
07:31AM EDT  The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue   Benzinga
Apr 19, 2021
06:01AM EDT  BrainStorm to Announce First Quarter Financial Results and Provide a Corporate   PR Newswire
Apr 14, 2021
11:51AM EDT  TENX: HELP Results & New Asset to Boot   Benzinga
Mar 24, 2021
08:59AM EDT  The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping   Benzinga
07:51AM EDT  BrainStorm Cell Therapeutics Inc. (BCLI) said that its phase 2 study, which evaluated NurOwn or MSC-NTF cells as a treatment for progressive multiple sclerosis, achieved the primary endpoint of safety and improvements were observed in secondary endpoints spanning neurologic function, cognition, and biomarkers.   RTTNews
07:47AM EDT  BrainStorm Cell Stock Surges As NurOwn Aces Mid-Stage Multiple Sclerosis Study   Benzinga
07:13AM EDT  BrainStorm Reports Positive Data In Phase 2 Study Evaluating NurOwn As Treatment For Progressive MS; Stock Surges   RTTNews
07:12AM EDT  BrainStorm Announces Topline Data In Phase 2 Study Evaluating NurOwn As A Treatment For Progressive MS; Study Achieved PRimary Endpoint Of Safety, Improvements Observed In Secondary Endpoints   Benzinga
07:01AM EDT  BrainStorm Announces Positive Topline Data in Phase 2 Study Evaluating   PR Newswire
Mar 4, 2021
08:12AM EST  The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company   Benzinga
Feb 27, 2021
02:13AM EST  Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Brainstorm Cell Therapeutics Inc. (BCLI) Investigation   Business Wire
Feb 23, 2021
08:03AM EST  BrainStorm to Present at SVB Leerink 10th Global Healthcare Conference   PR Newswire
Feb 22, 2021
02:51PM EST  Mid-Afternoon Market Update: Dow Jumps Over 100 Points; Cooper Tire Shares Jump   Benzinga
12:11PM EST  Mid-Day Market Update: Nasdaq Tumbles 250 Points; Celsion Shares Spike Higher   Benzinga
10:13AM EST  Mid-Morning Market Update: Markets Open Lower; DISH Network Profit Beats Views   Benzinga
09:02AM EST  FDA Concludes BrainStorm's ALS Cell Therapy Lacks Substantial Data For Submission; Shares Drop   Benzinga
08:10AM EST  BrainStorm Announces FDA Concluded From Initial Review That Current Level Of NurOwn Clinical Data Does Not Provide The Threshold Of Substantial Evidence That FDA Is Seeking To Support A Biologics License Application   Benzinga
08:05AM EST  BrainStorm Announces High-Level FDA Feedback on NurOwn(r) ALS Clinical   PR Newswire
Feb 9, 2021
09:03AM EST  BrainStorm Announces Feedback From FDA Type-C Meeting On Future NurOwn Manufacturing Plan   Benzinga
09:03AM EST  BrainStorm Says Pleased With FDA Type C Meeting Outcome And Guidance On Requirements For Future Semi-automated Process   RTTNews
09:03AM EST  BrainStorm Announces Feedback from FDA Type-C Meeting on Future NurOwn(r)   PR Newswire
Feb 5, 2021
10:14AM EST  Brainstorm Cell Therapeutics shares were trading higher after Maxim Group upgraded the stock from Hold to Buy. The company also issued FY20 EPS guidance.   Benzinga
10:03AM EST  Benzinga's Top Ratings Upgrades, Downgrades For February 5, 2021   Benzinga
08:56AM EST  Maxim Group Upgrades Brainstorm Cell to Buy   Benzinga
Feb 4, 2021
08:35AM EST  Earnings Scheduled For February 4, 2021   Benzinga
07:25AM EST  Brainstorm Cell FY20 EPS $(1.07) vs $(1.06) In FY19   Benzinga
07:22AM EST  The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs   Benzinga
07:01AM EST  BrainStorm Announces Full Year 2020 Financial Results and Provides a Corporate   PR Newswire
Jan 30, 2021
01:19PM EST  The Week Ahead In Biotech: Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More   Benzinga
Jan 28, 2021
08:31AM EST  BrainStorm-Cell Therapeutics to Announce Fourth Quarter and Fiscal Year 2020   PR Newswire
Jan 20, 2021
09:09AM EST  BrainStorm Cell Therapeutics Highlights Publication Of Preclinical Data Showing Potential Of NurOwn Derived Exosome-Based Treatment For COVID-19 Acute Respiratory Distress Syndrome   Benzinga
09:09AM EST  Potential of a NurOwn(r) Derived Exosome-Based Treatment for COVID-19 ARDS   PR Newswire
Dec 28, 2020
07:02AM EST  BrainStorm Cell Therapeutics Issues 2020 Letter To Shareholders   Benzinga
07:00AM EST  BrainStorm Issues 2020 Letter to Shareholders   PR Newswire
Dec 18, 2020
07:21AM EST  BrainStorm Says All Dosing Completed In Ongoing Phase 2 Trial Evaluating NurOwn As A Treatment For Progressive MS   RTTNews
07:03AM EST  BrainStorm Announces Completion Of All Dosing In NurOwn Phase 2 MS Study   Benzinga
Dec 14, 2020
07:18AM EST  BrainStorm Announces Initiation Of NurOwn Expanded Access Program   RTTNews
07:02AM EST  Brainstorm Cell Therapeutics Announces an Expanded Access Program for ALS   Benzinga
07:01AM EST  BrainStorm Announces NurOwn(r) Expanded Access Program   PR Newswire
Nov 23, 2020
07:09AM EST  BrainStorm to present NurOwn Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND   Benzinga
07:01AM EST  BrainStorm to present NurOwn(r) Phase 3 Clinical Trial Results at 31st   PR Newswire
Nov 17, 2020
02:46PM EST  Mid-Afternoon Market Update: Nasdaq Turns Positive; Cinedigm Shares Slide   Benzinga
12:37PM EST  Mid-Day Market Update: Sequential Brands Gains After Q3 Results; Brainstorm Cell Therapeutics Shares Plunge   Benzinga
10:38AM EST  Mid-Morning Market Update: Markets Open Lower; Walmart Beats Q3 Views   Benzinga
10:26AM EST  Yahoo Finance Trending Stocks For Tuesday, Nov. 17, 2020: TSLA, FCEL, COST, HD, PLUG, WMT, CVS, ABBV, WBA, GDRX, SE, VTRS, AMZN, LXRX, CTIB, BCLI, WWR, DQ, MOGO, SQBG, BLNK, RAD, MCK, RIDE, BMY, TMUS, RMED, MAPT, IQ   Benzinga
09:41AM EST  Stocks Trading Near 52-Week Lows Just After Open On Tuesday, Nov. 17, 2020: DQ, GDRX, FIIIU, PRFX, BCLI   Benzinga
07:45AM EST  BrainStorm Cell Therapeutics Inc. (BCLI) reported topline results from double-blind placebo-controlled phase 3 trial evaluating NurOwn as a treatment for Amyotrophic lateral sclerosis. The trial did not reach statistically significant results. The company noted that this clinical trial included a more severely affected ALS population compared to other recent ALS clinical trials.   RTTNews
07:39AM EST  BrainStorm Cell Shares To Resume Trade At 8 a.m. EST   Benzinga
07:33AM EST  UPDATE: BrainStorm Says 'biomarker analyses confirmed NurOwn resulted in a statistically significant increase of neurotrophic factors and reduction in neurodegenerative and neuroinflammatory biomarkers'   Benzinga
07:33AM EST  UPDATE: BrainStorm Says NurOwn Showed Clinically Meaningful Treatment Response vs Placebo   Benzinga
07:32AM EST  BrainStorm Says Topline Results From NurOwn Phase 3 ALS Studydid Not Meet Statistical Significance Results   RTTNews
07:32AM EST  BrainStorm Cell Therapeutics Reports Topline Results From NurOwn Phase 3 Amyotrophic Lateral Sclerosis Study: Did Not Meet Statistical Significance In Primary Endpoint   Benzinga
07:32AM EST  BrainStorm Says Topline Results From NurOwn Phase 3 ALS Studydid Not Meet Statistical Significance Results   RTTNews
07:30AM EST  BrainStorm Announces Topline Results from NurOwn(r) Phase 3 ALS Study   PR Newswire
Nov 11, 2020
02:26PM EST  Brainstorm Cell Option Alert: Dec 18 $12.5 Calls Sweep (5) near the Ask: 54 @ $5.284 vs 4841 OI; Ref=$11.75   Benzinga
Oct 26, 2020
06:12AM EDT  BrainStorm Selects RR&D As Partner To Expedite Site Selection And Design Services In The U.S.   RTTNews
06:04AM EDT  BrainStorm Selected RR&D to Expedite Site Selection and Design Services for its Manufacturing Facility for NurOwn in the U.S.   Benzinga
06:01AM EDT  Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement   PR Newswire
Oct 22, 2020
09:10AM EDT  Catalent, BrainStorm Cell Therapeutics Report Partnership To Manufacture Mesenchymal Stem Cell Platform, NurOwn, No Terms Disclosed   Benzinga
09:01AM EDT  Catalent and BrainStorm Cell Therapeutics Announce Partnership for   GlobeNewswire Inc
Oct 19, 2020
08:00AM EDT  BrainStorm To Present NurOwn Exosome Preclinical ARDS Outcomes At Virtual New York Stem Cell Foundation Conference Oct. 20   Benzinga
07:58AM EDT  BrainStorm Announces Scientific Presentation of NurOwn(r) Exosome Preclinical   PR Newswire
Oct 15, 2020
07:17AM EDT  BrainStorm Cell Therapeutics Q3 Loss Per Share $0.14 Vs Loss $0.25 Last Year   RTTNews
07:05AM EDT  Brainstorm Cell Q3 EPS $(0.14) Beats $(0.26) Estimate   Benzinga
07:01AM EDT  BrainStorm Announces Financial Results for the Third Quarter of 2020 and   PR Newswire
04:08AM EDT  Earnings Scheduled For October 15, 2020   Benzinga
Oct 12, 2020
01:46PM EDT  Brainstorm Cell Option Alert: Dec 18 $20 Calls Sweep (11) above Ask!: 85 @ $6.665 vs 770 OI; Earnings 10/15 Before Open Ref=$16.775   Benzinga
06:00AM EDT  BrainStorm to Present at the 2020 Cell & Gene Meeting on the Mesa   PR Newswire
Oct 2, 2020
01:00AM EDT  BrainStorm Cell Therapeutics to Announce Third Quarter Financial Results and   PR Newswire
Sep 30, 2020
05:28AM EDT  BrainStorm Announced Scientific Presentation at the Annual NEALS Meeting   Benzinga
Sep 29, 2020
06:02AM EDT  BrainStorm Appoints William White As SVP, Head Of Market Access & Pricing   RTTNews
06:01AM EDT  BrainStorm Appoints William K. White as Senior Vice President, Head of Market   PR Newswire
Sep 16, 2020
07:35AM EDT  Brainstorm Announces Grant Of New Japanese Patent For NurOwn   RTTNews
07:30AM EDT  Brainstorm Announces Grant of a New Japanese Patent for NurOwn(r)   PR Newswire
Sep 3, 2020
09:00AM EDT  BrainStorm to Present at Scientific Conferences in September   GlobeNewswire Inc
Sep 2, 2020
08:33AM EDT  BrainStorm Appoints Anthony Waclawski As EVP, Global Head Of Regulatory Affairs   RTTNews
08:30AM EDT  BrainStorm Appoints Pharmaceutical Veteran Anthony Waclawski as   GlobeNewswire Inc
Aug 25, 2020
07:42AM EDT  BrainStorm to Present Data Linking MRI Measures to Functional Improvement in Progressive Multiple Sclerosis Sept. 11-13   Benzinga
07:40AM EDT  BrainStorm to Present Data Linking MRI Measures to Functional Improvement in   PR Newswire
Aug 19, 2020
08:23AM EDT  BrainStorm Publishes New Data Supporting Proposed NurOwn Mechanism In ALS, Progressive MS And Alzheimer's Disease   RTTNews
08:23AM EDT  BrainStorm Announces Publication of New Preclinical Data Supporting Proposed NurOwn Mechanism In ALS, Progressive MS, Alzheimer's Disease   Benzinga
08:14AM EDT  BrainStorm Announces Publication of New Preclinical Data Supporting Proposed   PR Newswire
Aug 10, 2020
07:42AM EDT  BrainStorm to Present at the 40th Annual Canaccord Genuity Growth Conference   PR Newswire
Aug 5, 2020
07:19AM EDT  Brainstorm Cell Q2 EPS $(0.25) Beats $(0.26) Estimate   Benzinga
07:15AM EDT  BrainStorm Cell Therapeutics Q2 Net Loss $7.39 Mln Vs. Net Loss $4.90 Mln Last Year   RTTNews
07:01AM EDT  BrainStorm Announces Financial Results for the Second Quarter of 2020 and   PR Newswire
04:21AM EDT  Earnings Scheduled For August 5, 2020   Benzinga
Jul 27, 2020
07:59AM EDT  BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and   PR Newswire
Jul 23, 2020
07:21AM EDT  BrainStorm Cell Reports Successful Completion Of First Milestone For Treatment Of Coronavirus Infection: Intratracheal Admin. Of Exosomes Extracted From MSC's Using NurOwn Resulted In Statistically Significant Improvement In Multiple Lung Parameters   Benzinga
07:00AM EDT  Intratracheal administration of exosomes extracted from MSCs using NurOwn technology resulted in statistically significant improvement in multiple lung parameters in a mouse model   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC